As with other targeted cancer therapies, cancer cells can develop resistance mechanisms, such as compensatory upregulation of other telomere-binding proteins or alternative lengthening of telomeres (ALT) pathways (Cesare and Reddel 2010a). This evidence concerns the gene GPT and cancer.